Potential of triple-drug therapy to accelerate lymphatic filariasis elimination

Affiliations

¹ Department of Livestock and One Health, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, L3 5RF, UK. Electronic address: l.kelly-hope@liverpool.ac.uk.

Comment

Louise Kelly-Hope. Lancet Infect Dis. 2022 Aug.

. 2022 Aug;22(8):1099-1100.

doi: 10.1016/S1473-3099(22)00063-9. Epub 2022 May 6.

¹ Department of Livestock and One Health, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, L3 5RF, UK. Electronic address: l.kelly-hope@liverpool.ac.uk.

No abstract available

Conflict of interest statement

I declare no competing interests.

Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial.
Laman M, Tavul L, Karl S, Kotty B, Kerry Z, Kumai S, Samuel A, Lorry L, Timinao L, Howard SC, Makita L, John L, Bieb S, Wangi J, Albert JM, Payne M, Weil GJ, Tisch DJ, Bjerum CM, Robinson LJ, King CL. Laman M, et al. Lancet Infect Dis. 2022 Aug;22(8):1200-1209. doi: 10.1016/S1473-3099(22)00026-3. Epub 2022 May 6. Lancet Infect Dis. 2022. PMID: 35533701 Free PMC article. Clinical Trial.